Non-exclusive rebate agreement for oxybutynin-containing medicines

Summary

The tender concerns the conclusion of a non-exclusive rebate agreement for medicines containing oxybutynin for the period from 1 September 2026 to 31 August 2028, with an option to extend it once by 12 months. This is a medicines procurement in which DAK-Gesundheit intends to conclude rebate agreements with as many interested pharmaceutical companies as possible. The bidder must note that the agreement applies only to the specified active substance and dosage form PFT, and it ends automatically when an exclusive contract enters into force.